The global prefilled syringes market is growing at 9.1% CAGR owing to rising incidences of chronic and lifestyle diseases like heart diseases, diabetes, and autoimmune diseases, technological development, increased usage of self-injecting parenteral devices, and supportive regulation by the government particularly regarding needlestick legislations. Furthermore, the mounting awareness about the advantages associated with prefilled syringes among patients and medical professionals and the rising number of biologics and biosimilars in the pharmaceuticals market will drive the growth of the global prefilled syringes market. The prefilled syringes are novel devices that deliver drugs with enhanced accuracy, are affordable, efficient, accessible, sterilized, and safe.

The COVID-19 outbreak had a positive demand for prefilled syringes as it reduces the risk of needlestick injuries. Thus, to increase the production of vaccines for coronavirus, the manufacturers are growing their production capacity. For example, the U.S. government has entered into a deal of USD 138 million with the syringe providers to produce 100 million prefilled syringes for the COVID-19 vaccine by the end of 2020 and more than USD 500 million in 2021.

Request to get a free sample copy at https://www.vynzresearch.com/healthcare/prefilled-syringes-market/request-sample

Based on material, the glass prefilled syringes dominate the market as it provides benefits like prevention of oxygen and water vapor to interact with drug compounds, compatible with several filling machines, and seamless integration in pharmaceutical companies. Moreover, it has a strong barrier property that makes it suitable for prefilled syringes and is widely adopted in therapeutic areas like blood stimulants, vaccines, and therapeutic proteins to increase the product life span.

North America dominates the prefilled syringes market owing to the increasing geriatric population, growth of the biologics and biosimilars market, increased adoption of self-injecting devices, increased acceptance of patient safety measures, robust adoption of prefilled syringes in the region. Moreover, the presence of key industry players having a strong distribution network will propel the growth in the region.

Becton, Dickinson and Company (BD), has invested approximately $ 1.2 billion over four years to improve its prefilled syringe manufacturing technology and capabilities.

The prominent players in the prefilled syringe industry include Becton, Dickinson and Company, Weigao Group, Gerresheimer AG, SCHOTT AG, Catalent, Inc., West Pharmaceutical Services, Inc., Ompi, Vetter Pharma International GmbH, Nipro Corporation, and MedPro Inc.

Source: VynZ Research